By Fineline Cube 
Zhejiang State‑owned Capital Operation Co., Ltd. (ZSCO) and Guobang Pharmaceutical (SHA: 605507) announced a strategic partnership aimed at accelerating Guobang’s multi‑sector expansion. ZSCO has injected RMB 790 million into the company through a negotiated transfer, acquiring a 6.85 % stake that positions the state‑owned asset manager as a key growth enabler.
Investment Highlights
- Capital Injection – RMB 790 million provides Guobang with fresh liquidity to pursue aggressive growth in high‑margin sectors such as pet drugs, novel drug discovery, contract development & manufacturing organization (CDMO) services, and advanced materials.
- Strategic Alignment – ZSCO’s investment is complemented by its long‑term commitment to support Guobang’s expansion, including industry mergers & acquisitions, technology partnerships, and global market entry.
- Governance & Oversight – ZSCO will secure board representation and participate in strategic decision‑making, ensuring alignment of objectives between the state‑owned investor and the publicly listed company.
Future Growth Strategy
Guobang plans to leverage the partnership to:
- Scale Pet Drug Portfolio – Expand its pipeline of veterinary therapeutics, capitalizing on a growing global pet‑care market.
- Accelerate New‑Drug R&D – Deploy increased R&D budget toward high‑potential indications, leveraging ZSCO’s industrial network for technology transfer.
- Build CDMO Capabilities – Expand contract manufacturing services to serve both domestic and international clients, creating a new revenue stream.
- Develop New Materials – Invest in next‑generation biomaterials and delivery systems to support both pharmaceutical and medical‑device applications.
Vision for a Global Life‑Tech Hub
The partnership aims to transform Guobang into a globally influential life and health technology innovation hub. By combining ZSCO’s capital resources, industrial expertise, and strategic network with Guobang’s commercial momentum and product pipeline, the alliance is poised to deliver sustained value to shareholders while advancing China’s position in the global life‑science arena.-Fineline Info & Tech